E-viri
Recenzirano
Odprti dostop
-
Wozniak, Antoinette J.; Schneider, Bryan; Kalemkerian, Gregory P.; Daly, Bobby; Chen, Wei; Ventimiglia, Jaclyn; Nagasaka, Misako; Zauderer, Marjorie G.
Clinical lung cancer, 09/2023, Letnik: 24, Številka: 6Journal Article
•Novel therapies are needed for the treatment of malignant pleural mesothelioma (MPM).•Agents targeting angiogenesis such as bevacizumab have a role in the treatment of MPM.•Nintedanib had modest activity involving prolonged stable disease in a small group of patients.•Immunotherapy is now important in the treatment of MPM but angiogenesis inhibitors in combination with immunotherapy and/or chemotherapy may still have a role.•It is very important to discover biomarkers that can help with patient selection to individualize treatment.•Participation in clinical trials evaluating novel agents remains very important in advancing treatment strategies.
